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Abstract: The growing evidence of the involvement of purine compounds in signaling, of nucleotide
imbalance in tumorigenesis, the discovery of purinosome and its regulation, cast new light on
purine metabolism, indicating that well known biochemical pathways may still surprise. Adenosine
deaminase is important not only to preserve functionality of immune system but also to ensure a
correct development and function of central nervous system, probably because its activity regulates
the extracellular concentration of adenosine and therefore its function in brain. A lot of work has
been done on extracellular 5′-nucleotidase and its involvement in the purinergic signaling, but also
intracellular nucleotidases, which regulate the purine nucleotide homeostasis, play unexpected
roles, not only in tumorigenesis but also in brain function. Hypoxanthine guanine phosphoribosyl
transferase (HPRT) appears to have a role in the purinosome formation and, therefore, in the
regulation of purine synthesis rate during cell cycle with implications in brain development and
tumors. The final product of purine catabolism, uric acid, also plays a recently highlighted
novel role. In this review, we discuss the molecular mechanisms underlying the pathological
manifestations of purine dysmetabolisms, focusing on the newly described/hypothesized roles
of cytosolic 5′-nucleotidase II, adenosine kinase, adenosine deaminase, HPRT, and xanthine oxidase.
Keywords: cytosolic 5′-nucleotidase II; adenosine kinase; adenosine deaminase; hypoxanthine
guanine phosphoribosyl transferase; xanthine oxidase; uric acid
1. Introduction
Purine and pyrimidine nucleotides, nucleosides, and bases play several very important roles
in cells. It is universally accepted that their synthesis from amino acids and sugars occurs mainly
during the G1 and S phases of cell cycle to meet the high nucleotide demand during proliferation [1].
Nonproliferating cells, which need a smaller amount of nucleotides, rely mainly on catabolism and
salvage, and in complex organisms these two pathways not always take place in the same cell or
organ [2]. Enzymes involved in both de novo and salvage pathways are synthesized in greater
amount during G1/S and early S phases of cell cycle [3]. The flux of substrates and intermediates
through the de novo pathway is regulated mainly by the aggregation of a purinosome that, bringing
together the enzymes involved in the pathway, strongly increases the rate of purine synthesis. In fact,
it was demonstrated that the six enzymes catalyzing the 10 steps of purine biosynthesis, can cluster
near mitochondria and microtubules to form dynamic multienzyme complexes referred to as a
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“purinosome” [4]. The purinosome aggregation is driven by the absence of preformed purines in the
medium, indicating that both de novo and salvage pathways cooperate to meet the objective to supply
the correct amount of nucleotides, nucleosides, and bases for the cell requirements in any phase of
the cell cycle [1]. The purinosome assembly is also dependent on several distinct proteins such as
Hsp90, casein kinase II, and hypoxanthine guanine phosphoribosyltransferase (HPRT) and also on
small compounds such as inhibitors of microtubule polymerisation and G-protein coupled receptors
agonist, as well as on mitochondrial performances [1]. De novo synthesis is feedback regulated by its
final products adenosine 5′-monophosphate (AMP), inosine 5′-monophosphate (IMP) and guanosine
5′-monophosphate (GMP), which are allosteric inhibitors of 5-phosphoribosyl-1-pyrophosphate (PRPP)
amidotransferase (PPAT) [5], while it is increased in the presence of PRPP which is both substrate
and allosteric activator of the same enzyme [6] (Figure 1). Conversely, the purine salvage pathway
is mainly regulated by the level of expression of enzymes and their kinetic characteristics and
substrate concentrations, particularly of PRPP, which is a cosubstrate for adenine, hypoxanthine,
and guanine salvage [7] (Figure 2). Therefore, PRPP appears to be an important regulator in common
to both pathways [6,7]. As shown in Figure 2, the purine salvage pathway and purine catabolism
are strictly correlated. The first catabolic step is catalyzed by 5′-nucleotidases which generate
nucleosides from nucleoside monophosphates. Among the six cytosolic isoenzymes of 5′-nucleotidases,
cytosolic 5′-nucleotidase-I (cN-I) (specific for AMP) and cytosolic 5′-nucleotidase II (cN-II) (specific for
IMP-GMP) are allosterically regulated by adenylic compounds [8,9]. While cN-I is mainly expressed in
muscle, cN-II is an ubiquitous, highly regulated, and structurally conserved enzyme present in all the
eukaryotic organisms with the exception of yeasts [8]. It has been demonstrated that cN-II activity
is involved in the regulation of concentration of purine compounds, ribose-1-phosphate, and PRPP
as a function of energy charge and of phosphorylated compounds such as 2,3 bisphosphoglycerate
and diadenosine tetraphosphate [8]. In fact, cN-II is the regulated enzyme in the IMP-GMP cycle
(Figure 2). In the presence of allosteric activators, cN-II dephosphorylates IMP or GMP, generating
inosine or guanosine, which in turn can be split into ribose-1-phosphate and hypoxanthine or guanine.
The purine bases are in part salvaged back to IMP or GMP and in part discharged as such or as uric
acid, while ribose-1-phosphate can be utilized to salvage purine or pyrimidine bases, through the
action of nucleoside phosphorylases, or isomerized into ribose-5-phosphate and then utilized for PRPP
synthesis [10]. CN-II is usually highly expressed in cells and organs with high nucleic acid turnover
and in tumors [8]. The effect of cN-II silencing or hyperexpression has been studied in several tumor
cell models [11–13], demonstrating that the enzyme hyperexpression is followed by a strong decrease
of all triphosphorylated purine and pyrimidine nucleosides [14]. Conversely, cN-II silencing causes an
increase of the intracellular concentration of the same compounds [11,14]. In some cell models, the level
of cN-II expression reflects on proliferation and on drug resistance [15]. All of these observations
indicate that cN-II plays a fundamental role in the regulation of nucleotide concentration inside the cell
probably through both its hydrolytic activity and the regulation of intracellular PRPP concentration.
Among the purine nucleosides generated by hydrolysis of nucleoside monophosphate catalyzed by
cytosolic 5′-nucleotidases, adenosine is the only one that can be phosphorylated back to nucleoside
monophosphate, by adenosine kinase (ADK) located in the cytosol [16]. Deoxyguanosine kinase
activity is present and active in mitochondria [17], but no kinase activities specific for guanosine or
inosine are present in the cytosolic compartment of eukaryotic cells [18]. Adenosine can be generated
outside or inside the cell by nucleotide dephosphorylation, can cross the membrane following its
concentration gradient and plays a number of regulatory roles through the interaction with specific
receptors (A1R, A2AR, A2BR, and A3R). Typically A1R and A3R are coupled with the Gi/o family
of G-proteins which inhibit cyclic AMP production, whereas A2AR and A2BR stimulate cyclic
AMP production via Gs. Furthermore, all the adenosine receptors activate at least one subfamily
of mitogen activated protein kinases (MAPK) [19]. Accordingly, adenosine exerts a multitude of
functions such as modulation of neuron–glia signaling and neurodevelopment [20]. Furthermore,
the nucleoside plays an important role in the control of innate and adaptive immune system [21].
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As mentioned above, extracellular adenosine can arise from the catabolism of extracellular ATP.
ATP is secreted by a number of cell types and can interact with two families of specific receptors:
P2XR, ion-gated channels with neuromodulatory functions, and P2YR, coupled with G-proteins.
Purinergic signaling is involved in neuron–glial interactions [22] as well as in learning, memory, sleep,
locomotor activity, mood, motivation, and in pathological brain function such as trauma, ischemia,
stroke, neurodegenerative diseases, and neuropsychiatric disorders [23–28]. Adenosine, inside the
cell can be directly phosphorylated by ADK or deaminated by adenosine deaminase (ADA) into
inosine, that can in turn be converted into hypoxanthine and then salvaged as IMP or leave the cell
as hypoxanthine or uric acid (Figure 2) [29]. The final product of purine catabolism is uric acid that,
far from being a mere catabolite to be excreted, has known alternate fame and fortune. It has been
described as a very good antioxidant, able to substitute for ascorbate that cannot be synthesized in
humans, for the protection of different cells and organs from reactive oxyradicals [30]. Conversely,
many epidemiological studies have shown the relationship between uric acid and different disorders
such as obesity, metabolic syndrome, hypertension, and coronary artery disease [31]. Clinicians and
investigators recognized serum uric acid concentration as a very important diagnostic and prognostic
factor of many multifactorial disorders [32]. In this review, we intend to describe the more recent
results on the impact of cN-II, ADA, ADK, HPRT, and xanthine oxidase (XOD) activities and their
relationship with the molecular mechanisms leading to several pathologies.
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Figure 1. Purine de novo synthesis and its regulation. PRPP (5-phosphoribosyl-1-pyrophosphate)
is synthesized from ribose-5-phosphate (Rib-5-P) by PRPS (PRPP synthetase). Six enzymes catalyze
the ten steps required to convert PRPP into IMP: PPAT (PRPP amidotransferase), trifunctional GART
(phosphoribosylglycinamide synthetase/phosphoribosyl glycinamide transformylase/ phophoribosyl
aminoimidazole synthetase), FGAMS (phosphoribosyl glycinamidine synthase), bifunctional PAICS
(phosphoribosyl aminoimidazole arboxylase/phosphoribosyl aminoimidazole su cinocarboxamide
synthetase), ADSL (ade ylosuccinate lyase), and bifunctional ATIC (5-aminoimidazole-4-carboxamide
ribonucleotide transformylase/IMP cyclohydrolase). IMP is converted to IMP and GMP. AdSS:
Adenylosuccinate synthase, IMPDH: IMP dehydrogenase, GMPS: GMP synthetase. PRA:
phosphoribosylamine. +: activation; −: inhibition.
Int. J. Mol. Sci. 2018, 19, 3598 4 of 29
Int. J. Mol. Sci. 2018, 19, x 4 of 29 
 
 
Figure 2. Purine salvage and catabolism. APRT: adenine phoshoribosyltransferase, ADK: adenosine 
kinase, ADA: adenosine deaminase, cN-I: cytosolic 5′-nucleotidase I, cN-II: cytosolic 5′-nucleotidase 
II, HPRT: hypoxanthine-guanine phosphoribosyltransferase, PNP: purine nucleoside phosphorylase, 
XOD: xanthine oxidase, Ade: adenine, Ado: adenosine, Gua: guanine, Guo: guanosine, Hyp: 
hypoxanthine, Ino: Inosine, PRPP: 5-phosphoribosyl-1-pyrophosphate, Rib-1-P: ribose-1-phosphate. 
The yellow box: the purine cycle. 
2. Cytosolic 5′-Nucleotidase II (cN-II) 
2.1. CN-II and Spastic Paraplegia 
As already mentioned, cN-II is an essential enzyme for the regulation of purine compound pool. 
Recent findings indicate a possible alternative way of action of the enzyme. In fact, an interaction 
between cN-II and ice protease-activating factor (Ipaf) [33] has been established, which allows us to 
hypothesize that cN-II, via interaction with Ipaf, may be involved, at some level, in the regulation of 
the inflammatory process.  
To date, the direct involvement of cN-II into a clearly defined pathology has been assessed in 
just one single case: autosomic recessive spastic paraplegia 45 (SP45) [34–38]. Hallmark features of all 
hereditary spastic paraplegias (HSPs) are axonal degeneration and progressive lower limb spasticity 
caused by loss of corticospinal tract function and significant corpus callosum and white matter 
pathology. Based on their additional manifestations, HSPs are further classified as uncomplicated or 
complicated. Complicated HSPs often exhibit different grades of intellectual disability, epilepsy, 
optic atrophy, deafness, peripheral neuropathy, ataxia, and skin abnormalities [37]. Dursun et al. [34] 
first reported five patients suffering from SP45 all born from consanguineous unaffected parents. The 
authors did not relate the pathology directly to NT5C2 (the gene coding for cN-II), but they mapped 
the genes responsible for SP45 in the area 10q24.3-q25.1. A few years later, Novarino et al. [35] 
identified in the same family a truncating mutation at the very N-terminal of cN-II (R29→Stop). In 
the same study the authors described four other families in which different mutations in NT5C2 gene 
(one frameshift-mutant, two splice-mutants, and another stop-mutant) were responsible for SP45 
phenotype in homozygous subjects whereas the heterozygous parents did not show any of the 
features. Since then, three more reports have associated cN-II mutations with SP45 [36–38]. The first 
one described a Qatari family with a mutation in intron 14 leading to an alternative splicing of mRNA 
with the production of a shorter form of cN-II missing the 58 amino acids of exon 14 (G330 to S387) 
without any downstream frameshift [36]. Nevertheless, the expected shorter form of cN-II was not 
detectable in immunoblots of blood samples of affected individuals. Furthermore, the heterologous 
expression of the mutated cN-II revealed high instability of this enzyme form. Three more individuals 
of Arab origin suffering from SP45 (all of them offspring of consanguineous marriages) have been 
i r 2. ri sal a e an catabolis . : adenine phoshoribosyltra sfer s , : a e si
i ase, ADA: adenosine deaminase, cN-I: cytosolic 5′-nucleotidase I, cN-II: cytos lic 5′-nucleotidase II,
HPRT: hypoxanthi e-guanine phosphorib syltransfera e, PNP: purine nucleosid phosphorylase, XOD:
xanthine oxidase, Ade: adenin , A o: adenosine, Gua: guanine, Guo: gua osine, Hyp: hypoxanthine,
Ino: Inosine, PRPP: 5-phosphoribosyl-1-pyrophosphate, Rib-1-P: ribose-1-phosphate. The yellow box:
the purine cycle.
2. Cytosolic 5′-Nucleotidase II (cN-II)
2.1. CN-II and Spastic Paraplegia
As already mentioned, cN-II is an essential enzyme for the regulation of purine compound pool.
Recent findings indicate a possible alternative way of action of the enzyme. In fact, an interaction
between cN-II and ice protease-activating factor (Ipaf) [33] has been established, which allows us to
hypothesize that cN-II, via interaction with Ipaf, may be involved, at some level, in the regulation of
the inflammatory process.
To date, the direct involvement of cN-II into a clearly defined pathology has been assessed in
just one single case: autosomic recessive spastic paraplegia 45 (SP45) [34–38]. Hallmark features of all
hereditary spastic paraplegias (HSPs) are axonal degeneration and progressive lower limb spasticity
caused by loss of corticospinal tract function and significant corpus callosum and white matter
pathology. Based on their additional manifestations, HSPs are further classified as uncomplicated
or complicated. Complicated HSPs often exhibit different grades of intellectual disability, epilepsy,
optic atrophy, deafness, peripheral neuropathy, ataxia, and skin abnormalities [37]. Dursun et al. [34]
first reported five patients suffering from SP45 all born from consanguineous unaffected parents.
The authors did not relate the pathology directly to NT5C2 (the gene coding for cN-II), but they
mapped the genes responsible for SP45 in the area 10q24.3-q25.1. A few years later, Novarino et al. [35]
identified in the same family a truncating mutation at the very N-terminal of cN-II (R29→Stop). In the
same study the authors described four other families in which different mutations in NT5C2 gene
(one frameshift-mutant, two splice-mutants, and another stop-mutant) were responsible for SP45
phenotype in homozygous subjects whereas the heterozygous parents did not show any of the features.
Since then, three more reports have associated cN-II mutations with SP45 [36–38]. The first one
described a Qatari family with a mutation in intron 14 leading to an alternative splicing of mRNA with
the production of a shorter form of cN-II missing the 58 amino acids of exon 14 (G330 to S387) without
any downstream frameshift [36]. Nevertheless, the expected shorter form of cN-II was not detectable
in immunoblots of blood samples of affected individuals. Furthermore, the heterologous expression
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of the mutated cN-II revealed high instability of this enzyme form. Three more individuals of Arab
origin suffering from SP45 (all of them offspring of consanguineous marriages) have been described by
Straussberg et al. [37]. The exome sequencing performed on nine individuals of this family revealed
the expected pattern of a recessive inheritance of a new variant of cN-II, the first missense mutation
described, in which a leucine is substituted by a proline (c.1379C > T; p.Leu460Pro). The last reported
case of association of cN-II with SP45 described a new cN-II variant in which a 1954 bp deletion in the
NT5C2 gene led to the loss of exon 11 with the consequent deletion of 14 amino acids in cN-II enzyme
sequence (p.Lys258_Lys271del). This cN-II variant was found in three siblings of an Iranian family,
who exhibited the classic symptoms of complicated SP45 [38]. It would have been very interesting to
measure the residual cN-II activity in the patients suffering from SP45. Unfortunately, these data are
not available, it is therefore impossible to assess the impact of cN-II mutations on the regulation of
intracellular purine and pyrimidine compounds (see Figure 2) and the link between the fluctuations
in nucleotide concentration and SP45. In this regard, it is worth mentioning that in another central
nervous system (CNS) pathology, Lesch–Nyhan disease (LND) (see below in this review), a significant
hyperexpression of cN-II in red cells and fibroblasts was reported [39].
2.2. CN-II and Cancer
Many papers demonstrate that cN-II activity is involved in resistance to a number of nucleoside
analogs utilized as drugs in the therapy of several kind of tumors, mainly hematological malignancies
such as acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL) or acute lymphoblastic
leukemia (ALL), but also of some solid tumors, such as non-small cell lung cancer [40,41]. The resistance
occurs since cN-II activity can dephosphorylate the phosphorylated form of the nucleoside analog
which represents the active drug [15]. Many studies have been performed on patients carrying
either alteration in expression levels or mutant forms of cN-II, and on the clinical relevance that
these mutants could have on the outcome of the treatment with several nucleoside analogs (mainly
cladribine, fludarabine, cytarabine, gemcitabine, 6-mercaptopurine (6-MP), or 6-thioguanine). For a
better insight on this matter the reader is referred to exhaustive previously published reviews [15,40,42].
Herein we discuss the latest reports on the subject that greatly contribute to elucidate the role of cN-II
into the relapses of ALL treated with thiopurines.
Tzoneva et al. [43], using a knock-in mouse model for expression of mutant cN-II-(R367Q),
the most frequent of the 32 different cN-II mutant alleles to date described in relapse-ALL,
demonstrated that this gain-of-function mutant induced resistance to 6-MP both in vitro and in vivo.
Leukemia cells expressing cN-II-(R367Q) treated in vitro with 6-MP showed an evident resistance to
the purine analog when compared to the cells expressing wild type cN-II (control cells). Moreover,
the treatment with 6-MP of leukemic mice harboring the mutant allele of cN-II failed to cause remission,
while control mice had a clear dose-dependent response to the drug. These results led the authors
to hypothesize that these gain-of-function mutant alleles were responsible in vivo for the resistance
to chemotherapy with 6-MP in patients harboring these mutations, being also the cause of the early
relapses. Indeed, using the droplet PCR analysis, they also showed in ALL lymphoblasts the presence
of two more mutated gain-of-function alleles, P414A and R39Q, during complete remission period,
37 days before the onset of relapse. Mutant R39Q was detectable also in samples taken at the date of
the diagnosis, even though in very low amounts. The authors pointed out that, in the absence of 6-MP,
T-ALL cells harboring the R367Q mutation proliferated in vitro considerably slower when compared
with control cells and in vivo had both delayed entry in S phase and tumor progression. Moreover,
lymphoblasts carrying R367Q exhibited a 17-fold reduction, compared to control cells, in the capability
to initiate leukemia in transplantation experiments. The authors explain this loss-of-fitness of the
R367Q phenotype with the depletion of the cN-II substrates (IMP, XMP, and GMP) with a consequent
increased release into the media of the final products of the catabolism (inosine, guanine, hypoxanthine,
xanthosine, xanthine, and uric acid). According to the authors, this cN-II gain-of-function mutant made
the T-ALL lymphoblasts much more dependent on the rate of purine de novo synthesis, and therefore
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much more sensitive to drugs targeting this pathway. A series of experiments, both in vitro and in vivo,
with several gain-of-function mutants (R367Q, R238W, K359Q, and D407A) clearly demonstrated that
cells harboring the mutations were much more sensitive than control cells to the action of mizoribine,
an inhibitor of IMPDH, the enzyme responsible for the replenishment of the guanylate pool (Figure 1).
Moreover, supplementation of guanosine in the culture media suppressed the effect of mizoribine.
In vivo, treatment with mizoribine induced an evident anti-leukemic response in mice with R367Q
phenotype when compared with control mice, thus confirming their hypothesis [43].
Very recently, the structure of cN-II occurring in relapse leukemic cells was studied in order to
define the structural bases of the mutant gain-of-function enzymes [44,45]. In the absence of ATP,
the specific activity of cN-II is very low. In fact, the binding of the nucleotide drives a conformational
change toward a more active enzyme form [8]. The gain-of-function mutations of cN-II are all involved
in the stabilization of the structure of the G355-Q364 region (helix A) in an ordered α-helix form.
This region of the protein in the apo-form of control enzyme (not bound to ATP) has a loop structure
which turns to an α-helix form upon binding of ATP. This change of conformation facilitates the
binding of the substrates and the following catalysis [46]. Considering the heterozygosity of the
mutations in ALL, Hnizda et al. [44] and Dieck et al. [45] evaluated the activity of heterooligomeric
complexes formed by control and mutated subunits. Their in vitro and cellular studies demonstrated
that when a heterooligomer is formed, the activation state is transmitted from the mutated to the
control subunit [44].
Owing to the high cN-II expression observed in tumor cells and its involvement in drug resistance,
cN-II inhibition has been proposed as new therapeutic approach in tumors [15]. To support this
idea, cN-II silencing or hyperexpression has been performed in several cancer cell models [11,14].
In the ADF glioblastoma cell line, cN-II hyperactivity was accompanied by an increase of proliferation
and resistance to gemcitabine and mitomycin C, while enzyme silencing caused a decrease of cell
proliferation [13]. Also in A548 lung cancer cell line, cN-II silencing caused a decrease of proliferation
and a metabolic switch from a more glycolytic to a more oxidative phenotype [11]. Finally, in a breast
cancer cell model (MDA-MB-231), cN-II silencing caused the activation of a complex mechanism
leading to an increase of antioxidant defenses and to a better capacity to respond to a low glucose
environment [12]. These very recent results indicate that cN-II is, directly or indirectly, related to
regulatory mechanisms that still need to be elucidated.
2.3. CN-II and Other Pathologies
The presence of single nucleotide polymorphisms (SNPs) in the NT5C2 gene (most of them in
untranslated regions) has been associated with many different pathologies, such as schizophrenia,
cardiovascular diseases, and others. Nevertheless, most of these reports are obtained from
genome-wide association studies (GWAS) and are not supported by more detailed studies. For more
information on this subject the reader is referred to the following databases: MalaCards (https:
//www.malacards.org/), GWAS (https://www.ebi.ac.uk/gwas/), and Open Target Platform (https:
//www.targetvalidation.org/).
3. Adenosine Kinase (ADK) and Adenosine Deaminase (ADA)
3.1. ADK
ADK is an abundant enzyme in mammalian tissues that catalyzes the transfer of the
gamma-phosphate from ATP to adenosine, thereby acting as a potentially important regulator of
concentrations of both extracellular adenosine and intracellular adenine nucleotides. ADK expression
changes during brain development—being neuronal at the first stages and enriched in astrocytes
later [47,48]—and in response to brain injury [49,50]. Human ADK consists of two alternatively spliced
forms which differ only at the 5′-end. Both isoforms show identical kinetics and both require Mg2+ for
activity [51]. ADK-large is nuclear and ADK-short is cytoplasmic. Kiese et al. [50] found developmental
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downregulation of nuclear Adk-Large transcripts in neurons and upregulation of cytoplasmic Adk-Short
transcripts in astrocytes.
3.2. ADK and Neurological Diseases
ADK mutations or alterations in ADK expression have been involved in several pathologies
including neurodevelopmental delay [52–55], epilepsy (reviewed in [56]) and gliomas [57,58]. Recently,
upregulation of ADK has been found in reactive astrocytes and a subpopulation of neurons in
lesions of Rasmussen encephalitis, a rare neurological disorder characterized by unihemispheric
inflammation, progressive neurological deficits, and intractable focal epilepsy [59,60]. Similarly,
upregulation of ADK has been reported in surgically resected human epileptic cortical specimens
from focal cortical dysplasia type IIB with balloon cells [61]. This dysplasia is a developmental
malformation of the cerebral cortex that is associated with pharmacoresistant epilepsy [62]. It has been
proposed that dysfunction of adenosine signaling is common in neurological conditions and that it can
explain comorbid phenotypes [63] such as epilepsy, Parkinson’s disease and Alzheimer’s disease (AD)
among others.
Transgenic mice with ADK knockout or hyperexpressing ADK through all the brain or in
specific regions have been a useful tool to uncover the role of ADK in synaptic plasticity, learning,
and epilepsy [64–66]. Transgenic mice with brain-wide or telencephalon ADK hyperexpression
showed dysregulation of brain adenosine which results in working memory deficiency and impaired
Pavlovian conditioned freezing [65], while mice with brain-wide deletion of ADK developed
spontaneous seizures and profound deficits in hippocampus-dependent learning and memory [66].
Humans with ADK deficiency showed hepatic encephalopathy, developmental delay, and cognitive
impairment [53,54]. Many actions of adenosine are mediated by adenosine receptors [23] while others
are receptor-independent [29]. Indeed, A2AR antagonists can attenuate neurological symptoms in
ADK deficiency [66] while intracellular adenosine acting on the transmethylation pathway, plays a role
in the modulation of epileptogenesis [67]. Transmethylation reactions require S-adenosylmethionine
as donor of the methyl group and generate S-adenosylhomocysteine (SAH) as a product, which is then
further converted into adenosine and homocysteine by SAH hydrolase (SAHH). ADK deficiency
leads to accumulation of adenosine, which reverses the SAHH reaction, leading to high levels
of SAH, which inhibits the transmethylation reactions [68]. Spontaneous recurrent seizures in
murine models were associated with disruption of adenosine homeostasis (increased ADK and
reduced adenosine), increased DNA methyltransferase activity and increased hippocampal DNA
methylation [67]. Intraventricular implantation of adenosine-releasing polymers restored methylation
to control levels and reduced seizure activity even after cessation of adenosine release from the
polymers. In addition, DNA methyl transferase inhibition reduced seizure susceptibility and epilepsy
acquisition [67]. Interestingly, genetic variants of ADK have been associated with the development of
post-traumatic epilepsy in humans [69]. Therefore, changes in adenosine metabolism, such as those
triggered by pathological hyperexpression of ADK or by genetic mutations, could be biomarkers for
epileptogenesis and also therapeutic targets to prevent epilepsy.
Other studies have demonstrated that ADK determines the degree of brain injury after ischemic
stroke in mice. When ischemia has been induced in transgenic mice with increased ADK expression in
striatum and reduced ADK expression in cortical forebrain, the infarct volume was increased in the
striatum and decreased in the cortex compared with WT controls [49].
The neuroprotective effects of adenosine suggest its use as a potential therapeutic agent for
various brain disorders. However, systemic application of adenosine is hampered by cardiovascular
side effects. In order to improve local delivery and raise the level of adenosine in CNS, adenosine
releasing polymers and cell-mediated cell therapy have been proposed. Indeed, human neuroepithelial
stem cells with ADK gene knockout were able to differentiate in cells exhibiting higher release of
adenosine compared to control cells [70].
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3.3. ADK and ADA in Glioma
Recent evidence indicates that ADK and ADA levels are related to glioma progression. ADK was
detected in the cytoplasm as well as in the nuclei of cells obtained from gliomas. ADA and ADK levels
were upregulated in patients with Grade II and Grade III gliomas compared to control subjects [57,58].
ADK and ADA, by regulating adenosine concentration, might also play a role in tumor growth
and apoptotic cell death in gliomas, modulating proliferation of glial and endothelial cells [71–73].
Extracellular adenosine reduced viability in rat glioma cells [71,72] and ADA reverted this effect [72].
Therefore, the higher expression of both enzymes is expected to increase tumor growth. However,
the in vivo effect may depend on the expression of the different adenosine receptors in tumoral
and peritumoral cells as well as on the oxygen levels. Interestingly, hypoxic niches of glioblastoma
induced tumorigenic properties of a small cell subpopulation called glioblastoma stem-like cells which
generated extracellular adenosine and were able to differentiate into endothelial cells [74]. The blockade
of A3AR reduced both the differentiation under hypoxia and blood vessel formation in vivo [73].
ADA and ADK expression was upregulated in peritumoral tissues derived from patients with epilepsy
compared to those without epilepsy [57,58], whereas the number of ADA-positive or ADK-positive
cells in tumor tissues was similar between glioma patients with and without epilepsy [58]. ADA activity
increased following induction of seizures in zebrafish, while pretreatment with anti-epileptic drugs
before the convulsant prevented the stimulatory effect on ADA activity [75]. Therefore, it appears that
increased ADA and ADK may reduce adenosine levels, decrease its inhibitory activity and lead to
epileptogenesis and progression of epilepsy in glioma patients.
One side effect of chemotherapy is neuropathic pain, that might be promoted by enhanced spinal
ADK levels through a mechanism dependent on astrocytes [76]. Chemotherapeutic agents such as
oxaliplatin caused ADK hyperexpression in reactive astrocytes and reduced adenosine signaling at the
A3AR subtype within the spinal cord in rodents. Dysregulation of ADK and A3AR signaling was found
to be associated with increased proinflammatory and neuroexcitatory interleukin-1β expression and
inflammasome activation, while the application of a selective A3AR agonist attenuated the production
of the inflammatory cytokine IL-1β and increased the release of the anti-inflammatory IL-10 [76].
3.4. ADA
ADA catalyzes the deamination of adenosine and deoxyadenosine. Mutations in the ADA gene
are among the most common causes for severe combined immunodeficiency (SCID). In the absence of
ADA activity, deoxyadenosine accumulates in extracellular compartments and within cells, where it is
converted by deoxycytidine kinase and/or ADK to deoxyadenosine monophosphate, which in turn is
converted to deoxyadenosine triphosphate (dATP). Intracellular dATP might generate DNA strand
breaks, inhibit ribonucleotide reductase, thereby impairing DNA synthesis and repair, induce apoptosis
in developing thymocytes and interfere with terminal deoxynucleotidyl transferase activity [77,78].
Additionally, deoxyadenosine inactivates SAHH, leading to accumulation of SAH (see above) and
inhibits the transmethylation reactions necessary for effective lymphocyte activation. The accumulation
of deoxyadenosine and dATP in lymphocytes is considered as the primary cause of lymphotoxicity.
Besides immune effects, ADA-SCID patients show skeletal, hepatic, renal, and lung alterations,
as well as neurological abnormalities and behavioral impairments. They include reduced verbal
expression, learning disability, hyperactivity, attention deficit, seizures, and hearing deficits [79–81].
Interestingly, reduced ADA activity has also been found in the serum of autistic children [82],
in association with a polymorphism in the ADA gene [83]. This rare low-activity polymorphism
was more likely found in children with mild mental retardation of unknown causes, when compared
to both healthy controls and children with moderate to severe mental retardation of known causes [84].
Although bone marrow transplant, PEG-ADA treatment or hematopoietic stem cell gene therapy
are able to improve the immunological/metabolic deficits, they cannot completely prevent the
onset or resolve pre-existing neurological defects [85–88]. It is difficult to ascertain whether the
neurological impairments are exclusively determined by the lack of ADA or are also a consequence of
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the complications from infections at early life. It is thought that different types of stress in early life
may particularly alter neuro-immune development with psychiatric consequences [89]. Adenosine
and deoxyadenosine accumulate when there is a deficit of ADA, and they might be responsible for the
alterations in the nervous system. Adenosine acts as a neuromodulator through a family of purinergic
G-protein-coupled receptors (A1R, A2AR, A2BR, and A3R), while ATP binds to P2XR and P2YR
(see introduction).
Recently, the extent of correction of neurological deficits after PEG-ADA treatment has
been studied in an animal model of ADA-SCID, the Ada−/− mouse [88], which showed many
features associated with ADA deficiency in humans, including systemic metabolic alterations and
immunodeficiency [90]. Brain size of Ada−/− mice was slightly reduced compared to Ada+/+.
Brains of 3-week-old Ada−/− mice showed ventriculomegaly but not myelination alterations or
neuronal loss [88]. In Ada−/− mice, ADA activity was undetectable, and adenosine increased in
total brain extracts from birth until their death, while adenosine levels in Ada+/+ mice remained low.
Lack of Ada led to alterations in explorative behavior, increased anxiety-like behavior, and reduced
pain sensitivity without modifying sensory or motor development at 15th postnatal day. Adora2a−/−
mice were hypoalgesic [91], suggesting that Ada−/−might have defects in A2AR signaling. Indeed,
the level of A2AR in Ada−/− and in PEG-ADA-treated mice was reduced compared to Ada+/+ brains.
Pain sensitivity showed a tendency to decrease after PEG-ADA treatment, without reaching wild
type levels [88]. ADA activity was not detected in the brain of PEG-ADA-treated Ada−/−mice, likely
because PEG-ADA cannot cross the blood–brain barrier. Adenosine metabolite levels in the brain of
PEG-ADA-treated mice were 10-fold lower than in untreated mice, but remained 3-fold higher than in
wild type. The authors hypothesized that brain adenosine metabolites could diffuse out of the brain
and could be detoxified peripherally by PEG-ADA. This could result in reduced adenosine levels in
the brain. Interestingly, the enzyme replacement therapy corrected the ventriculomegaly but not the
observed abnormalities in exploration and anxiety-like behavior. Therefore, some of the characteristics
of the Ada−/−mice could be due to alterations in the adenosine receptors [88].
3.5. ADA and Adenosine Receptors
Accumulating evidence suggests that ADA and adenosine receptors interact at the cell surface [92],
probably increasing receptor sensibility to adenosine. Indeed, ADA binding affected the quaternary
structure of A2AR [93] and A1R [94] and increased both agonist and antagonist binding. Under normal
conditions, endogenous adenosine modulated colonic motility via A2BR located in the neuromuscular
compartment. In the presence of bowel inflammation, this inhibitory control was impaired due to the
link between A2BR and ADA, which when catabolizing adenosine, prevented A2BR activation [95].
ADA acts not only as a catalyst, but also as a costimulator, an allosteric modulator and a cell-to-cell
connector [96]. Indeed, there is also evidence of the formation of trimeric complexes dipeptidyl
peptidase IV (CD26)-ADA-A2AR involving two cells. ADA could bridge T-cells (expressing CD26)
and dendritic cells (expressing A2AR) [96], but it is still unknown if this role is also played in the
nervous system and whether the ADA deficiency could affect the connection between nervous cells.
CD26 has been associated with a variety of pathologies, including tumors, but no correlation between
CD26 expression in gliomas and malignancy has been found [97].
3.6. ADA Inhibition and Apoptosis
It is known that accumulation of deoxyadenosine and/or adenosine can cause apoptotic death in
sympathetic neurons and adrenal chromaffin cells [98,99], in human astrocytoma and neuroblastoma
cells [100–102]. Adenosine also induced death of embryonic stem cell-derived motor neurons in
culture [103]. The effect of adenosine and deoxyadenosine may depend on the developmental stage of
the cell. In cultured chick sympathetic neurons, adenosine was lethal at earlier stages of development
but not later (i.e., when added to the culture from the time of plating up to 16 h).
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Deoxycoformycin (dCF), a powerful inhibitor of ADA [104], has been used alone or in combination
with other drugs for the treatment of several types of lymphocytic leukemia [105–108]. The combination
of deoxyadenosine and dCF is toxic for several cell lines of tumoral origin such as rat hepatoma
cells [109] and human colon carcinoma cell lines LoVo and HT29 [110–112]. The treatment with
deoxyadenosine and dCF in combination induced apoptosis in human astrocytoma and neuroblastoma
cell lines [100–102], but the underlying mechanisms seem to be different. In astrocytoma cells,
a reduction in the production of lactate preceded the effect of deoxyadenosine and dCF on cell
viability, suggesting a decreased glycolytic capacity, while neuroblastoma cells did not show changes
on glycolytic capacity. Both cell lines showed a decrease in mitochondrial reactive oxygen species
production probably due to an impairment in mitochondrial function. The observed increase in
mitochondrial mass could possibly help to cope with the reduction in mitochondrial activity. In both
cell lines, deoxyadenosine must be phosphorylated in order to exert its cytotoxic effect; however,
a decrease in the energy charge was observed in astrocytoma but not in neuroblastoma cells. Therefore,
it appears that one of the roles of ADA is to avoid the accumulation of the potentially toxic adenosine
and/or deoxyadenosine. This action can be useful in fighting tumors, since ADA inhibition could
lead to increased cell death, but at the same time, decrease of ADA activity might increase the risk
of neurological dysfunction, including cognitive deficits. Recently, another contribution of ADA
inhibition in the suppression of tumor progression has been highlighted. It has been demonstrated
that dCF suppresses growth of 4T1 murine breast cancer in vivo, and in vitro experiments have shown
that dCF reduces migration, invasion and adhesion of 4T1 cells and the involvement of A2AR and
A3R activation in these processes [113].
4. Hypoxanthine-Guanine Phosphoribosyltransferase (HPRT)
4.1. HPRT and LND
LND is a severe X-linked hereditary disorder caused by the lack of the enzyme HPRT.
The metabolic symptoms of this disorder are hyperuricemia leading to gout and impaired kidney
functions, accompanied by neuropsychiatric problems such as dystonia, spasticity, and self-injurious
behavior, the hallmark feature of LND [114]. The overproduction of uric acid can be explained by
the conversion of unrecycled guanine and hypoxanthine into uric acid and the increase in the rate of
purine de novo synthesis, which has been longly ascribed to the accumulation of PRPP and reduced
inhibition by end-products [115]. While the treatment with allopurinol, an inhibitor of XOD, reduces
plasma concentrations of uric acid, no effects on neurological symptoms are observed [115]. So far,
the link between the metabolic defect and the neurological manifestations remains largely unknown.
There is strong evidence that the neurological impairments in LND are mainly due to the effects of
HPRT deficiency on both the development of dopaminergic neurons [116] and on the modulation of
GABAergic and glutamatergic neurotransmission [115]. Positron-emission tomography of brains of
LND patients revealed decreased dopamine production and storage [117] and a marked reduction
in dopamine transporters [118]. Despite these earlier reports which indicate that LND primarily
involves the basal ganglia, later on, magnetic resonance imaging studies revealed substantial white
matter volume reduction in LND patients in brain regions which is consistent with the neurobehavioral
phenotype of LND patients, thus arguing for more complex mechanisms beyond the basal ganglia [119].
4.2. HPRT Deficiency and the Accumulation of Potentially Toxic Metabolites
A huge amount of work has been done to find the molecular link between the metabolic defect
and neuronal development in LND patients. It has been hypothesized that the excess hypoxanthine
accumulating as a consequence of HPRT deficiency triggers the neurological abnormalities [120].
Indeed, primary astroglia cultures from HPRT-deficient transgenic mice [121] and a rat neuroma
cell line deficient of HPRT [122], both used as an in vitro model of LND, showed a 15-fold increase
in extracellular hypoxanthine, due to the lack of recycling to IMP. A significant accumulation of
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hypoxanthine was observed also in human neuroblastoma HPRT-deficient sublines [123] and in
cultures of fibroblasts obtained by LND patients [124]. In a rat neuroblastoma B103 cell line and its
HPRT-deficient mutant (B103-4C), hypoxanthine significantly increased the proliferation of both cell
lines with a greater effect on the mutant cells. Also, differentiation was affected by hypoxanthine,
but while an enhancement was observed in control cells, a decrease was reported for the mutant
cells [125]. The authors suggest that exposure to hypoxanthine during fetal or perinatal development
of the nervous system of LND subjects, through a still unknown mechanism, probably involving
the binding to benzodiazepine receptor [115,126], may cause abnormal arborization of dopaminergic
neurons, which has been suggested to be responsible for the symptoms of LND [127]. A deregulation
of genes involved in early neuronal development by hypoxanthine has been reported in a human
embryonic carcinoma neurogenesis model (NT2/D1) [128]. The authors report that, during retinoic
acid-induced differentiation, excess hypoxanthine, through unidentified mechanisms, significantly
increased the expression of genes associated with neural development such as wingless-type
MMTV integration site family, member 4 (WNT4), belonging to the Wnt/β-catenin pathway,
and engrailed homeobox 1, a transcription factor known to play a key role in the specialization
and survival of dopamine neurons. Hypoxanthine appears also to enhance the expression of
tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis, and type 1 dopamine receptors
A2AR and 5-hydroxytryptamine (serotonin) receptor 7, whose hyperexpression characterize early
neurodevelopmental processes [128]. Similarly, an imbalance in adenosine, dopamine, and serotonin
receptors has been reported in lymphocytes of LND patients [129]. This supports the hypothesis
that the neurological impairments of LND patients may be related to an imbalance of more than
one neurotransmitter. In fact, adenosine, dopamine, and serotonin receptors, belonging to the
G-protein coupled family, seem to be integrated through intermembrane receptor–receptor interactions,
and adenosine receptor disturbance may be followed by alterations in dopamine and serotonin
receptor [129]. Also, a hypothesized deficiency of guanine-based purines has been invoked as
responsible for the neurological manifestations in LND [115]. Guanosine is recognized as an important
modulator of glutamatergic neurotransmission, promoting glial re-uptake of L-glutamate [130].
Deutsch et al. [115] hypothesized that the lack of HPRT in LND does not allow the salvage of
guanine-based nucleotides, thus leading to a depletion of guanine-based purines in areas critical to
normal synaptic neurotransmission, including the area of glutamatergic synapses. Indeed, in neurons,
the rate of the degradative deamination of guanine to xanthine by guanase is significantly greater than
its incorporation into nucleotides by HPRT [131], therefore, owing to the lack of salvage of guanine in
LND, guanine appears to be channeled towards degradation.
Using peripheral blood lymphocytes obtained from controls and LND patients, Torres et al. [132]
demonstrated that HPRT deficiency causes a reduction in adenosine uptake, and this reduction is more
pronounced if hypoxanthine is present in the culture medium. This could be attributed to dysfunction
of the adenosine equilibrative transporters, and in particular, the NBTI-insensitive (ENT2) transporters
appeared to be predominantly affected, hypoxanthine being a competitive inhibitor of adenosine
transport [132,133]. Inhibitors of adenosine transport have been reported to increase extracellular
cerebral adenosine levels [134,135] by inhibiting entry of the nucleoside into cells which actively
metabolize adenosine through ADA and/or ADK [136]. Therefore, it is assumed that inhibition
of adenosine uptake, due to extracellular hypoxanthine accumulating in LND patients, causes an
extracellular accumulation of adenosine with enhanced stimulation of adenosine receptors [120].
While adenosine in CNS inhibits neurotransmitter release by the A1 receptor, the nucleoside can also
induce opposite effects through the A2AR. These receptor subtypes are expressed in different areas of
the developing brain, and a correct integration between excitatory and inhibitory stimuli is regulated
by their timely recruitment. In LND, excitatory A2AR-mediated signaling is likely predominant
compared to A1R-mediated inhibitory processes [25]. Recently, it has been reported that hypoxanthine
infusion in striatum of young Wistar rats increases neuroinflammatory parameters perhaps through
oxidative misbalance [137] and induces neuroenergetic impairment resulting in ATP depletion which
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leads to mitochondrial dysfunctions and cell death by apoptosis [138]. Therefore, the authors suggest
that these processes may be involved, at least in part, in the pathogenesis of the neurological disorders
of LND patients.
An accumulation of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) (also known as
ZMP) has been reported in LND patients [139] and in a patient lacking AICAR formyltransferase/IMP
cyclohydrolase (ATIC), an enzyme belonging to the de novo purine synthesis, which catalyzes
the two-step conversion of ZMP into IMP. The ATIC-deficient patient presented devastating
neurological symptoms, including seizures, developmental delay, hypotonia, autistic features and
brain anomalies [140]. ZMP is an AMP mimetic known to activate the AMP-activated protein kinase
(AMPK) [141], and the treatment of undifferentiated neuroblastoma cells with AICA-riboside activated
AMPK and exerted a neurotoxic action through the apoptotic program [142], possibly triggered by
the prolonged and uncontrolled AMPK activation. In this regard, López [143] hypothesized that ZMP
may be the toxic compound in LND. Indeed, the prolonged activation of AMPK may exert noxious
effect on dopamine synthesis [144], cell viability and morphology.
4.3. HPRT and the Formation of Purinosome
After the discovery of purinosome [4], many attempts have been made in order to identify
the signal responsible for the aggregation/disaggregation of the de novo purine synthesis enzymes.
Chan et al. [145] demonstrated that the assembly/disassembly of the purinosome depends on the
cell cycle and correlates with cellular demands for purine biosynthesis encountered during the cell
cycle. In particular, the number of purinosome-containing cells peaks in G1 phase in HeLa cells
grown and maintained in a purine-depleted condition. The purine demand decrease correlates
with the decrease in purinosome-positive cells in S and G2/M phases of cell cycle. HPRT-deficient
fibroblasts also exhibited the greatest purinosome formation in G1 phase, however high levels of
purinosomes were also observed in the S and G2/M phases [145]. Accordingly, Fu et al. [124],
using cultures of fibroblasts obtained from HPRT-deficient patients and normal healthy controls grown
under purine-rich conditions, demonstrated that the formation of purinosomes was significantly
greater in fibroblasts of LND patients, suggesting that the lack of HPRT activates the de novo synthesis,
independently of the presence of preformed purines. The authors suggest that the increase of de
novo purine synthesis could compensate for the loss of purine recycling. However, the excreted uric
acid largely exceeds the amount of purine nucleotides necessary to compensate for the lack of purine
recycling, indicating a dysregulation of the purine de novo synthesis. Using a synchronized human
colon carcinoma cell line, Fridman et al. [3] showed that purine nucleotide synthesis by both the
de novo and salvage pathways increases markedly when cells progress from G1 into the S-phase,
and that this increase is driven by a raise in PRPP concentration. Since the increased de novo synthesis
correlates with the formation of purinosome [145], it is conceivable that PRPP, which accumulates in
case of HPRT deficiency, favors the formation of purinosome, which could explain the dysregulation
of this synthetic pathway in LND patients.
4.4. HPRT and the Purinergic Signaling
While studying the high-affinity GTPase activity of G-proteins in membrane from primary
human skin fibroblasts, rat B103 neuroblastoma cells and mouse Neuro-2a neuroblastoma cells,
Pinto et al. [146] unexpectedly found that the membrane low-affinity nucleoside 5-triphosphatase
activity (NTPase) was decreased up to 7-fold in HPRT deficiency. This first report, based on
the measurement of enzyme activity, was unable to reveal the molecular identity of the involved
NTPases. Therefore, RT-PCR and restriction enzyme digestion of amplified cDNA fragments were
used to evaluate the expression, in B103 and Neuro2a cells, of different isoforms of ecto-nucleoside
5′-triphosphate diphosphohydrolases (NTPDases), a likely candidate enzyme family responsible for the
altered NTPase activity in HPRT deficiency [147]. Collectively, the expression of NTPDase isoforms in
HPRT deficiency depends on the specific cell type and species studied, so that, depending on the overall
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change in NTPDase isoenzyme expression and the specific activities of isoenzymes, the net result may
be an increase or a decrease in NTPDase activity [147]. Since extracellular ATP regulates cell function
through P2XRs, belonging to the class of ligand-gated ion channels, and through P2YRs, belonging to
the class of G-protein coupled receptors, the hypothesis of an association between HPRT deficiency
and abnormalities in P2XR and P2YR-mediated signaling has been tested in rat B103 neuroblastoma
cells [148]. The measurement of the effect of various nucleotides on both the influx of Ca2+ across the
plasma membrane and the mobilization of Ca2+ from intracellular stores, associated with quantitative
RT-PCR studies, revealed that two ligand-gated ion channel subtypes (P2X2R and P2X4R), and five
G-protein coupled receptors (P2Y2R, P2Y4R, P2Y12R, P2Y13R and P2Y14R) are downregulated in
HPRT deficiency [148]. Therefore, an altered purinergic Ca2+ signaling in a HPRT-deficient cell model
for LND has been reported. Later on, Mastrangelo et al. [149] demonstrated a downregulation of
P2Y1R expression in HPRT-knockdown human induced pluripotent stem (iPS) and embryonic stem
(ES) cells. HPRT-deficient iPS cells show highly impaired CREB phosphorylation and constitutively
activated ERK1/2 and insensitivity to ATP. ERK proteins belong to the MAPK family, which responds
to growth factors and regulates proliferation and differentiation [150]. Therefore, HPRT may play a role
in determining aspects of neurogenesis and neurodevelopment during embryogenesis by regulating
P2Y1R purinergic signaling. HPRT deficiency may hamper the function of embryonic and developing
CNS cells, thus contributing to the neuropathology of LND [149]. In fact, using HPRT-deficient
ES cells as model and global transcriptomic characterization as method, it has been demonstrated
that HPRT-knockdown causes a switch from neuronal to glial gene expression [151]. Even though
the exact nature of the responsible mechanisms has not been definitively established, a possible
candidate could be the aberrant expression of Sox2, a gene vital for stem cell pluripotency and
for the neuronal/glial cell fate decision [152]. The persistent and increasing expression of Sox2
in the differentiating HPRT-deficient murine ES cells appears to be consistent with the impaired
neurogenesis typical of HPRT deficiency [151]. Moreover, HPRT-deficiency causes dysregulated
expression of key genes such as achaete-scute family bHLH transcription factor 1 (Ascl1), forkhead
box P1 (Foxp1), and transcription factor B-cell leukemia 11b (Bcl11b), essential for striatal patterning,
and the gene encoding dopamine- and cAMP-regulated phosphoprotein 32 (Darpp-32) in immortalized
mouse striatal neural stem cells. On the other hand, HPRT-deficiency upregulates the expression
of the brain-derived neurotrophic factor (BDNF)/TrkB pathway, and thereby confers protection to
HPRT-deficient striatal cells against reactive oxygen species-mediated cell death [153]. The authors
suggest that the purine metabolic defect caused by HPRT-deficiency, while providing neuroprotection
to striatal neurons, affects key genes and signaling pathways that may underlie the neuropathogenesis
of LND [153]. In addition, HPRT deficiency in murine ES cells dysregulates many cellular functions
controlling cell cycle and proliferation, RNA metabolism, DNA replication and repair, protein synthesis,
and others [151]. Also, an increased expression of the miR181a in HPRT-deficient human dopaminergic
SH-SY5Y neuroblastoma cells has been identified, which could lead to aberrant expression of many
target genes involved in embryonic development of CNS [154]. Therefore, it is conceivable that neural
aberrations of LND result from combinatorial and multigenic defects. Intriguingly, many of the
dysregulated genes during neurogenesis of HPRT-deficient murine ES cells are also found aberrantly
expressed in AD and other CNS disorders [155]. This suggests that, even though the gene expression
dysregulations in AD are not resulting directly from aberrant expression of HPRT, disturbances of
purine metabolism and purinergic signaling are likely to contribute to dysfunction in AD and possibly
other CNS disorders.
4.5. HPRT and Cancer
In 1990, our research group reported that HPRT activity was significantly higher in tissue samples
obtained from patients operated upon for intestinal and breast cancer with respect to peritumoral
tissues [156]. The increased activity appears to confer selective growth advantage to cancer cells,
favoring a metabolic flux towards purine mononucleotides, which can be used as precursors for
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the synthesis of nucleic acids. In addition, a progressive and statistically significant increase in
HPRT activity was observed with clinical parameters of human colon carcinoma diffusion [157].
Recently, several research groups resumed this topic, postulating an emerging role for HPRT in
cancer. Müller et al. [158] using quantitative PCR, found that HPRT was detectable in cultured human
MDA-MB-231 breast carcinoma cells, primary tumors, and tumor-infiltrated lungs of SCID-mice
injected with human MDA-MB-231 breast carcinoma cells, but undetectable in normal mouse lungs,
and that the human HPRT mRNA content in lungs of mice correlated with the size of the tumor.
More recently, using immunohistochemistry staining, the level of HPRT has been evaluated in normal
and malignant tissues from human lung, breast, colon and prostate [159]. Although a significant
variability within patients with regard to the relative expression of HPRT both in normal and malignant
tissues has been observed, an overall trend showing upregulation of HPRT in cancerous tissues has
been reported. With the exception of lung cancer, the authors claim that the upregulation of HPRT
is independent of cancer grade or stage, and they hypothesize that HPRT could be utilized as an
early biomarker because it appears to be upregulated in cancer regardless of stage [159]. A surface
expression of HPRT has been reported in lung cancer cell lines, although the reason for this external
presentation is presently unknown [160]. As HPRT is a potential cancer-associated antigen, the authors
hypothesize that HPRT could become a target for emerging immunotherapies designed to attack
cancer cells which display unique surface proteins [161].
5. Xanthine Oxidase (XOD)
5.1. XOD and Xanthine Dehydrogenase (XDH)
Hypoxanthine and xanthine oxidation to uric acid can be catalyzed by two different activities:
XDH and XOD, both expressed by the same protein [162]. During the dehydrogenase reaction electrons
from substrates are transferred to FAD and eventually to NAD+ which is reduced to NADH, while in
the oxidase reaction, the reduced FAD donates electrons to oxygen, thus producing hydrogen peroxide
and superoxide. XDH can be converted to XOD by disulfide formation or proteolysis [163]. It is highly
possible that in certain pathological conditions this transformation occurs in vivo, but it is extremely
difficult to know the relative concentration of the two forms in living organisms and cells [162].
However, it would be very interesting to have an idea about the presence of the two forms, because
both of them generate uric acid with antioxidant activity, but XOD generates also activated oxygen
species. As a consequence, enzyme inhibitors can cause a decrease of antioxidant defense that can be
dangerous for brain function [31], but can also decrease the oxygen radical generation, protecting cells,
and organs expressing XOD from oxidative stress [164].
5.2. XOD and Uric Acid
Uric acid is the metabolic end product of purine catabolism in humans. Generally, in other
mammals, uric acid is transformed into allantoin which is a more soluble compound. Catabolism
of purine compounds occurs in all organs of the human body, but the final step of xanthine and
hypoxanthine oxidation into uric acid occurs only in tissues expressing XOD, mainly liver and small
intestine [165]. A considerable XOD activity has also been measured in mammary glands where it
appears to be involved in the correct formation of the envelop of milk fat droplets [166]. Because of the
high level found in colostrum and early milk, XOD activity has long been considered an important
host defense molecule in the intestine of breastfed infant [167].
Humans are unable to metabolize uric acid because of a mutation in the uricase gene, following
the food shortage and global cooling 15 million years ago, which presumably yields a survival
advantage [168]. The consequence of uricase inactivation is the appearance of urate levels that are
much higher in humans in comparison to other mammals. It has been demonstrated that uric acid
is a potent antioxidant accounting for approximately 50% of the antioxidant power in humans [169].
The loss of uricase in hominids, along with the fact that in humans 90% of uric acid filtered by the
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kidneys is reabsorbed, suggests that uric acid is a somehow beneficial compound and not just a
mere waste product. Indeed, uric acid is no longer considered biologically inert since it acts as a
pro- and antioxidant, neuroprotector, neurostimulant, and activator of the immune response and
inflammation [170]. Nevertheless, hyperuricemia is associated with multiple diseases in humans
and this finding points to the deleterious effects of high concentrations of urate [32]. Consequently,
the manipulation of serum uric acid levels has become a popular strategy for the treatment of a
considerably high variety of diseases, and the research on the molecular links between uric acid and
several pathologies and particularly neurodegenerative disorders has been pushed forward [171].
The amount of plasma urate depends on the dietary intake of purines, mainly degraded in the intestinal
mucosa, and on the rate of their biosynthesis and excretion [31]. The major regulatory system for the
homeostasis of plasma urate depends on a four-component renal transport system which involves
glomerular filtration, reabsorption, secretion, and post-secretory reabsorption [172]. From several
studies a normal range of blood uric acid concentration can be defined between 120 and 380 µM
depending on gender and age [173].
5.3. Pathologies Associated with High Uricemia
Hyperuricemia has been implicated in the etiology of several diseases such as diabetes, chronic
kidney disease, coronary heart disease, and many others [174]. An increase of serum uric acid can
be caused by a defect in the proteins implied in its homeostasis, such as those involved in renal
urate clearance [175], or as a consequence of the assumption of food such as fatty meat, organ meat,
seafood, or high amount of fructose [176,177]. High levels of uric acid have been described also as
a consequence of an increase of the rate of purine synthesis, turnover, or catabolism (see above in
this review). A number of reviews and papers discuss the correlation between uric acid level and the
pathogenesis of several diseases [31]. Recently, XOD and uric acid have been reported to be involved
in the pathogenesis of the metabolic syndrome and insulin resistance. However, no clear explanation
has been advanced for the adverse effect exerted by XOD and uric acid [164,174]. Several papers
indicate a strong association between high concentration of circulating uric acid and inflammation
and cancer [178–180]. It has been hypothesized that uric acid plays an important role as a signaling
molecule mediating the inflammatory effects of hyperuricemia in adipocytes and leukocytes, and as
a promoter of tumor cell proliferation, migration, and survival [181]. Therefore, managing uric acid
levels may be relevant for the improvement of treatment strategies in patients in which hyperuricemic
disorders are associated with tumors [181].
Inhibitors of XOD have been widely utilized to contain the dangerous effects of uric acid
accumulation, because they cause a decrease of circulating uric acid concentration and an increase of
xanthine and hypoxanthine [182]. The effects of high hypoxanthine concentration, associated both
with XOD inhibition and HPRT deficiency, are described above in this review, while the possible
involvement of hypouricemia in the etiology of several neurodegenerative diseases will be discussed
in the following section.
5.4. Pathologies Associated with Low Uricemia
Uric acid is maintained through a complicated homeostatic mechanism, at a very high
concentration in blood, close to the limit of its solubility. As mentioned before, uric acid is potent
antioxidant, but it has been claimed that it is also a stimulator of the cerebral cortex [183]. The oldest
hypotheses of an influence of uric acid concentration on intelligence were based on the similarity
of the uric acid structure with some brain stimulants such as caffeine [184]. Since then several
authors have found significant positive correlation between uric acid concentration and higher
intelligence in children and adults [185,186]. Furthermore, a positive correlation exists between
gout and intelligence [183]. On the bases of these findings, a role in neuroprotection was hypothesized
for uric acid, reinforced by the observation that gout and multiple sclerosis are mutually exclusive [31].
Recently, many authors suggested that the neuroprotective action of uric acid was due to its antioxidant
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activity. In fact, the brain is very vulnerable to oxidative damage and requires a very efficient
antioxidant defense since it has a very high metabolic rate and a high presence of unsaturated fatty
acid in its membrane [187]. A metabolomic study pointed out that uric acid decreased in serum
of patients suffering from AD, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS) [188].
The role played by uric acid in serum and cerebrospinal fluid was mostly studied in Parkinson’s
disease, where oxidative stress plays a major role [189]. It was found that, not only uric acid inversely
correlated with the risk of developing the disease in the general population [190], but also that uric
acid level correlated with certain motor and non-motor disturbances [191]. In particular, patients with
higher serum uric acid were more likely to manifest resting tremor and less likely to develop other
non-motor disturbances such as mild cognitive impairment. An inverse association was also found
in patients with fatigue, the same observation was also reported in more severe form of fatigue such
as in acute ischemic stroke and chronic fatigue syndrome [192–194]. In a Parkinson’s disease mouse
model, it was demonstrated that uric acid administration resulted in a significant neuroprotection
for dopaminergic neurons probably through Nrf2-ARE-induced inhibition of oxidative damage and
neuroinflammation [195]. ALS patients were shown to have lower serum uric acid levels than healthy
individuals by several studies [188,196]. The decreased uric acid levels were correlated with the rate of
disease progression, further demonstrating the possible role of oxidative stress in the induction and
propagation of the disease, and the possible therapeutic role of uric acid administration [196]. Curiously,
it was also recently demonstrated that inhibition of XOD in ALS animal model, with non-purine analog
drugs, had a protective effect on motoneurons [197]. Further studies are necessary to unravel the causal
linkage between uric acid concentration and neurodegeneration, and in particular, in our opinion,
it would be necessary to investigate on the cause of the low uric acid concentration associated with
neurodegeneration. In some cases, this scarcity may be the consequence of a low purine turnover.
In this light, the paradoxical effect of XOD inhibition in ALS could be explained as a mean to increase
circulating hypoxanthine and guanine for purine nucleotide synthesis through salvage pathway,
necessary to sustain neuron energy supply. The general neuroprotective role exerted by uric acid
was also described in ischemic stroke; in fact clinical epidemiological studies demonstrated that
ischemic stroke patients with higher serum urate levels had better clinical outcomes upon hospital
discharge [198]. On the bases of all the observations listed above regarding the neuroprotective effects
exerted by uric acid, clinical trials of uric acid administration in acute ischemic stroke, as well as
in Parkinson’s disease were set up, demonstrating a certain degree of efficacy more pronounced
in women than in men [199,200]. Since women have substantially lower serum uric acid levels,
this observation is attractive and requires further investigation. Alternatively, inosine, a uric acid
precursor, has been found to improve outcomes, both in animal models and patients in a number of
neurological disorders [171,201,202]. In this case however, the effect exerted could be more difficult
to decipher because inosine is not only an uric acid precursor, but can increase purine supply for
nucleotide synthesis, ribose moiety for PRPP synthesis or energy supply and finally can also engage
adenosine receptors [203].
6. Concluding Remarks
Owing to the multitude of biological processes in which purines are involved, complex enzymatic
machinery has been built up in order to respond to the varying demands of the organism. Therefore,
it is not surprising that alterations in the activity of key enzymes of purine metabolism may lead
to severe pathological manifestations. Nevertheless, the consequences of enzyme dysfunctions are
sometimes surprising, unexpected and difficult to understand at the molecular level. Experimental
evidence suggests that disturbances of purine metabolism are likely to contribute to dysfunction in
AD and possibly other CNS disorders. An association between purine metabolism dysfunctions and
tumor progression has also been reported. In fact, tumor cells express a greater amount of cN-II,
which appears to confer resistance to several purine prodrugs commonly used in chemotherapy.
Also HPRT is upregulated in several solid tumors, thus favoring a metabolic flux towards purine
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mononucleotides, used as precursors for the synthesis of nucleic acids. As a consequence, a selective
growth advantage is given to cancer cells. ADA and ADK are upregulated in higher grade gliomas
but the relevance for tumor progression requires further research. Some metabolic manifestations of
purine enzyme dysfunctions that are clearly related to substrate accumulation or lack of product are
often associated with other manifestations, mainly neurological, that are not so clearly and directly
related to the enzyme dysfunctions. As an example, a complete lack of HPRT activity causes uric
acid accumulation which leads to kidney failure that can be reversed by XOD inhibition, but also a
very complex and severe neurological dysfunction that despite 60 years of studies and several very
interesting reports, still waits for a clear explanation. In ADA-deficient patients, a deoxyadenosine
accumulation has been observed, which leads to an increase of intracellular dATP concentration that
acts as a ribonucleotide reductase inhibitor and is lethal for cells proliferating at high rate. The same
patients, despite a substitutive ADA-PEG therapy, develop a variable degree of neurological and
cognitive impairments, possibly ascribable to an adverse effect exerted by adenosine accumulation on
the developing brain. However, the molecular basis of this effect still needs to be clearly addressed.
Although the study of the effects caused by cN-II mutations is still at the beginning, it is attractive
that the only hereditary disease linked to cN-II mutation, so far ascertained, is spastic paraplegia,
a multifactorial disease due to dysfunction of long axons in the spinal cord. Many old reports indicate
a positive correlation between high uricemia and intelligence; the consequence of these observations
might bring the reader to the conclusion that middle-aged men are more intelligent than young-men
and women, which is far from true. High uricemia has been also associated to several diseases such
as metabolic syndrome, diabetes, and cancer. The nature of this relationship is matter of debate but
the results are clear and point to an adverse effect exerted by high concentrations of uric acid. Indeed,
allopurinol and other more recently commercialized XOD inhibitors are among the most frequently
prescribed drugs in the highly developed countries. The consequence of XOD inhibition is a decrease of
uric acid and an increase of xanthine and hypoxanthine serum concentrations. However, as highlighted
in the present review, high concentrations of hypoxanthine may interfere with the purinergic signaling,
and low uric acid concentrations have been associated with neurodegenerative diseases.
Overall, many neurological aspects of a variety of diseases of unknown mechanism might rely on
a deficit or deregulation of the enzymes involved in purine metabolism. Therefore, we think that the
diagnosis of these neurological diseases could benefit from the measurement of the activities of purine
metabolizing enzymes, paving the way for new effective therapeutic approaches.
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Abbreviations
A1R adenosine receptor subtype 1
A2R adenosine receptor subtype 2
A3R adenosine receptor subtype 3
AD Alzheimer’s disease
ADA adenosine deaminase
ADK adenosine kinase
AICAR 5-aminoimidazole-4-carboxamide ribonucleotide
ALL acute lymphoblastic leukemia
AML acute myeloid leukemia
AMP adenosine 5′-monophosphate
AMPK AMP-activated protein kinase
ALS amyotrophic lateral sclerosis
ATIC AICAR formyltransferase/IMP cyclohydrolase
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Ascl1 achaete-scute family bHLH transcription factor 1
BDNF TrkB brain-derived neurotrophic factor
CD26 trimeric complexes dipeptidyl peptidase IV
CLL chronic lymphoid leukemia
CN-I cytosolic 5′-nucleotidase-I
CN-II cytosolic 5′-nucleotidase II
CNS central nervous system
Darpp-32 the gene encoding dopamine- and cAMP-regulated phosphoprotein 32
dCF deoxycoformycin
ENT2 adenosine equilibrative transporters NBTI-insensitive
ES embryonic stem cells
Foxp1 forkhead box P1
GMP guanosine 5′-monophosphate
HPRT the gene coding for HPRT
HPRT hypoxanthine guanine phosphoribosyl transferase
HSPs hereditary spastic paraplegias
IMP inosine 5′-monophosphate
IMPDH inosine-5′-monophosphate dehydrogenase
Ipaf ice protease-activating factor
LND Lesch–Nyhan disease
MAPK mitogen activated protein kinases
6-MP 6-mercaptopurine
NT5C2 the gene coding for cN-II
NTPDases 5′-triphosphate diphosphohydrolases
NTPase nucleoside 5-triphosphatase
PPAT 5-phosphoribosyl-1-pyrophosphate amidotransferase
PRPP 5-phosphoribosyl-1-pyrophosphate
P2XR purinergic receptor subtype 2X
P2YR purinergic receptor subtype 2Y
SAH S-adenosylhomocysteine
SAHH SAH hydrolase
SCID severe combined immunodeficiency
SNPs single nucleotide polymorphism
SP45 autosomic recessive spastic paraplegia 45
WNT4 wingless-type MMTV integration site family, member 4
XDH xanthine dehydrogenase
XOD xanthine oxidase
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